A rheumatologist or a trained physician in autonomic dysfunction can score each patient for hypermobility
Mejlhede MAB, Jepsen JB, Knudsen UB
In peptide research, this relationship is often described as a 1+1=3 effect due to the supra-additive nature of the secretagogues
Through downregulating monocyte chemoattractant protein-1 expression, semaglutide treatment, an FDA-approved GLP-1 RA medicine targeting Type II diabetes mellitus (T2DM) (Christou et al., 2019), inhibited monocyte migration and infiltration from the circulatory system to inflammatory regions (Pontes-da-Silva et al., 2022)
Whether Phase 3 confirms those numbers at scale is the question that will define retatrutides future
Here is a sample report of test results from Vibrant America